A Senate investigation led by Senator Maggie Hassan alleges that GSK's withdrawal of branded Flovent shifted costs and access problems onto asthma patients while allowing the company to avoid a large Medicaid inflation-rebate exposure. The March 16 report is a congressional minority staff finding, not a court judgment or a regulatory enforcement decision.
GSK stopped selling branded Flovent HFA and Flovent Diskus at the end of 2023. An authorized generic version of the inhaler, supplied through Prasco Laboratories, remained available. Although that product contains the same medicine as the branded version, the change in product code and commercial arrangements affected how Medicaid rebates, insurer formularies and pharmacy benefit managers treated it.
That distinction is central to the story. The dispute is not whether fluticasone propionate suddenly became a different medicine. It is whether replacing an established brand with an authorized generic disrupted coverage and reduced the inflation rebates that would otherwise have been owed on a product with a long pricing history.
The Report Connects the Withdrawal to a Rebate Change
Federal law requires drugmakers to pay additional Medicaid rebates when prices rise faster than inflation. A provision taking effect in 2024 removed the cap that had limited total Medicaid rebates to 100 percent of a drug's average manufacturer price. For some older drugs with years of price increases, the resulting rebate could exceed the amount Medicaid paid for the medicine.
Hassan's investigation says GSK faced an estimated $367.6 million in 2024 Medicaid rebates if branded Flovent stayed on the market. CNN reported the investigation's estimate that Medicaid instead paid more than $550 million that year for the replacement version, which did not carry the same accumulated rebate history. Those figures are estimates attributed to the Senate investigation, not independently audited totals.
The report describes the withdrawal as a strategy to escape that liability. GSK notified the FDA and other parties in advance, but the company did not restore the branded product after Hassan asked it to do so. The senator has said Congress should close the policy gap that allowed a replacement product to start without the older brand's inflation-rebate history.
That allegation requires careful wording. The timing and financial structure support congressional scrutiny, but intent remains contested. The available public record establishes the discontinuation, the authorized-generic arrangement and the rebate change. It does not convert Hassan's characterization of GSK's motive into an adjudicated fact.
An Authorized Generic Did Not Guarantee the Same Coverage
FDA defines an authorized generic as the brand-approved drug marketed without the brand name, either by the brand company or with its permission. It is the same drug product as the branded medicine and is marketed under the original New Drug Application. A conventional generic is made by another company under an Abbreviated New Drug Application and must demonstrate bioequivalence.
That regulatory equivalence did not ensure an administratively smooth substitution. The Boston Globe reported that a survey of 43 families found more than a quarter faced higher out-of-pocket costs after changing treatments. A separate survey of 226 clinicians found that more than half of respondents encountered prior-authorization difficulties for alternatives, along with shortages or problems matching patients to age-appropriate devices.
Those surveys describe reported experiences, not a randomized comparison capable of assigning every health outcome to the product withdrawal. They nevertheless show why an identical active medicine can become harder to obtain when a familiar product disappears from formularies and a replacement arrives under different contracting and reimbursement terms.
For patients using a maintenance inhaler, a coverage interruption is not merely a billing inconvenience. Fluticasone propionate is an inhaled corticosteroid used to reduce airway inflammation and prevent symptoms over time. It is not a rescue treatment for an acute asthma attack, and patients should not change or stop prescribed asthma medicine without discussing an alternative with a clinician.
GSK Disputes Responsibility for Coverage Decisions
GSK said it remained committed to ensuring access to respiratory medicines. According to the Boston Globe, the company said it supplied the authorized generic to a program offering free medicine to patients who could not afford it and capped eligible patients' out-of-pocket costs at $35 for nine inhalers that GSK markets.
The company also said it did not negotiate insurance coverage or cost for the Prasco authorized generic and that those decisions belonged to Prasco. Prasco did not respond to the Globe's request for comment. That answer separates GSK from later formulary negotiations, but it does not resolve the Senate report's broader question about who initiated the product transition and who benefited from the changed rebate treatment.
Insurers and pharmacy benefit managers also shaped the result. A medicine can carry a lower list price yet cost a plan more after rebates, or it can be clinically interchangeable while occupying a different formulary tier. A complete accounting therefore has to examine the manufacturer, authorized-generic partner, benefit managers and health plans rather than treating the pharmacy counter as the start of the problem.
The strongest public evidence supports a narrower conclusion than the original article claimed: families and clinicians reported access friction after the switch, and the Senate investigation tied GSK's decision to a substantial rebate exposure. Claims that every patient paid more, that costs tripled universally or that a specific increase in emergency visits was caused by the switch require evidence beyond what these sources establish.
A True Generic Adds Competition but Does Not Erase the Gap
On March 3, 2026, FDA approved Glenmark Specialty's fluticasone propionate inhalation aerosol, 44 micrograms per actuation, as the first generic of Flovent HFA. The approval covers maintenance treatment of asthma in patients aged four and older. FDA directed questions about availability to the manufacturer.
The Glenmark product differs commercially from the Prasco authorized generic because it received its own generic approval. That can introduce a competitor into a market that previously relied on a brand-authorized replacement. It does not guarantee that every pharmacy will stock it, every insurer will cover it or every patient will immediately pay less.
The approval also does not settle the policy dispute. A new competitor may improve future access while leaving the 2024 transition and its costs unresolved. Hassan says she is pursuing legislation to prevent another company from using a similar product replacement to shed an accumulated Medicaid rebate obligation, though a final legislative design was not detailed in the reviewed sources.
The hard lesson is administrative, not molecular. Keeping the same medicine available under a new label did not preserve the same route through formularies, rebates and pharmacy counters. If Congress wants inflation penalties to constrain prices, the obligation must survive product-code changes that leave the underlying drug and manufacturer-controlled supply arrangement substantially intact.
GSK is entitled to dispute the senator's account of intent, and the report should not be written as a legal verdict. But patient access cannot be treated as someone else's problem at every link in the chain. A rebate rule that disappears when a product is relabeled, a formulary that rejects the replacement and an assistance program that reaches only eligible patients can all be technically defensible while the prescription still fails at the counter. Any fix should be judged by whether maintenance treatment remains continuously obtainable, not by whether each company can explain its own narrow role.